Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H23Cl2N3OS |
Molecular Weight | 448.4103 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC1)c2ccccc2/C(/[H])=C\3/C(=O)N(CCS3)c4ccc(c(c4)Cl)Cl
InChI
InChIKey=LHYMPSWMHXUWSK-STZFKDTASA-N
InChI=1S/C22H23Cl2N3OS/c1-25-8-10-26(11-9-25)20-5-3-2-4-16(20)14-21-22(28)27(12-13-29-21)17-6-7-18(23)19(24)15-17/h2-7,14-15H,8-13H2,1H3/b21-14-
Molecular Formula | C22H23Cl2N3OS |
Molecular Weight | 448.4103 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Elzasonan (CP 448187) is a serotonin 1B/1D receptor antagonist. Elzasonan was primarily metabolized via oxidative N‐demethylation, N‐oxidation, and aryl hydroxylation. Pfizer was developing elzasonan for the treatment of anxiety and affective disorders however development has been discontinued.
CNS Activity
Originator
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 08:58:43 UTC 2021
by
admin
on
Sat Jun 26 08:58:43 UTC 2021
|
Record UNII |
933PJL964R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66885
Created by
admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
361343-19-3
Created by
admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
|
PRIMARY | |||
|
933PJL964R
Created by
admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
|
PRIMARY | |||
|
205683-28-9
Created by
admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
6914152
Created by
admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
|
PRIMARY | |||
|
C556408
Created by
admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
|
PRIMARY | |||
|
CHEMBL2110932
Created by
admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
|
PRIMARY | |||
|
C72755
Created by
admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
|
PRIMARY | |||
|
361343-19-3
Created by
admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
|
PRIMARY | |||
|
8240
Created by
admin on Sat Jun 26 08:58:44 UTC 2021 , Edited by admin on Sat Jun 26 08:58:44 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET->ANTAGONIST | |||
|
SALT/SOLVATE -> PARENT | |||
|
EXCRETED UNCHANGED |
FECAL
|
||
|
EXCRETED UNCHANGED |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
M6 accounted (average of six human subjects) for 5.6% (sum of M5 and M6) of the administered dose in feces
FECAL
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
sum of M5 and M6 counted for 5.6% of the administered dose in feces
FECAL
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||